Evidence map›Paper›PMID 42860544›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Tracking CDK1 Dynamics With a Novel Biosensor Mouse and Clinical Cohorts to Predict CDK4/6 Inhibitor Sensitivity in ER+ Breast Cancer.

Sarah Alexandrou, Kristine J Fernandez, Min Li Huang, Ewan K A Millar, Claire Vennin, Leila Eshraghi, Tan Dat Timothy Lam, Victoria Lee, Nyah C Brooks, Janett Stoehr and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Sarah AlexandrouSt Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0003-1186-6507
Kristine J FernandezGarvan Institute of Medical Research, Sydney, NSW, Australia.ORCID https://orcid.org/0009-0002-5509-6807
Min Li Huang *St Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, New South Wales, Australia.
Ewan K A Millar *Department of Anatomical Pathology, NSW Health Pathology, St George Hospital, Sydney, New South Wales, Australia.
Claire VenninSt Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, New South Wales, Australia.
Leila EshraghiSt Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, New South Wales, Australia.
Tan Dat Timothy LamGarvan Institute of Medical Research, Sydney, NSW, Australia.ORCID https://orcid.org/0009-0004-6758-073X
Victoria LeeGarvan Institute of Medical Research, Sydney, NSW, Australia.ORCID https://orcid.org/0000-0002-0701-8321
Nyah C BrooksGarvan Institute of Medical Research, Sydney, NSW, Australia.ORCID https://orcid.org/0009-0008-3383-8877
Janett StoehrGarvan Institute of Medical Research, Sydney, NSW, Australia.ORCID https://orcid.org/0000-0002-4198-3520
Cristian Guaman MendezGarvan Institute of Medical Research, Sydney, NSW, Australia.ORCID https://orcid.org/0000-0003-2676-2575
Douglas StrathdeeCancer Research UK Scotland Institute, Glasgow, Scotland, UK.ORCID https://orcid.org/0000-0003-2959-4327
David StevensonCancer Research UK Scotland Institute, Glasgow, Scotland, UK.
David HerrmannSt Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, New South Wales, Australia.
Sandra O'TooleGarvan Institute of Medical Research, Sydney, NSW, Australia.
Paul Timpson *St Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, New South Wales, Australia.
Max Nobis *Manchester Cell-Matrix Centre, Division of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK.ORCID https://orcid.org/0000-0002-1861-1390
C Elizabeth Caldon *St Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0003-1392-3472

Funding

Australian Government Research Training Program ScholarshipCancer Institute NSW 2020/CDF1071Cancer Institute NSW ECF011Cancer Institute NSW ECF012Cancer Research UK A31287Lysia O'Keefe FellowshipNational Breast Cancer Foundation IIRS-19-054National Breast Cancer Foundation IIRS-21-2017National Health and Medical Research Council 1188208National Health and Medical Research Council 2012837National Health and Medical Research Council 2016930St Vincent's Clinic FoundationSuttons family
6 · The paper itself

Abstract

High-risk estrogen receptor positive (ER+) early breast cancer (EBC) is managed with endocrine therapies and cyclin-dependent kinase (CDK) 4/6 inhibitors, although no standard molecular markers clinically identify these tumors. CDK1 lies immediately downstream of CDK4/6 but has not been investigated as a prognostic marker for ER+ disease. Here, we integrate real-time imaging of a novel Cdk1 activity biosensor mouse with clinical cohorts to establish CDK1 as a candidate biomarker of progression and therapeutic sensitivity. Using the MMTV-PyMT;MMTV-Cre;Cdk1-FRET biosensor mouse, we visualized Cdk1 upregulation in situ during the transition to invasive ductal carcinoma (IDC). Clinically, we identified that pCDK1

Indexed as

biosensor mousebreast cancerCDK1CDK4/6 inhibitioncell cycleendocrine therapy

Identifiers

PMID42860544
PMCPMC13655259

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.